Drugs / RZ700
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07333352 | Sep 2025 → Jul 2027 expected | pneumococcal infection | Shanghai Reinovax Biologics Co.,LTD | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RZ700 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07333352 ↗ |
| Known as | 24-Valent Pneumococcal Polysaccharide Conjugate Vaccine | “24-Valent Pneumococcal Polysaccharide Conjugate Vaccine (RZ700)” NCT07333352 ↗ |
| Modality | Vaccine | “24-Valent Pneumococcal Polysaccharide Conjugate Vaccine” NCT07333352 ↗ |
| Route | Intramuscular | “single intramuscular injection of the experimental vaccine or comparator control vaccineon the day of enrollment” NCT07333352 ↗ |